IL-12p35 Inhibits Neuroinflammation and Ameliorates Autoimmune Encephalomyelitis

Jin Kyeong Choi, Ivy M Dambuza, Chang He, Cheng-Rong Yu, Anita N Uche, Mary J Mattapallil, Rachel R Caspi, Charles E Egwuagu

Research output: Contribution to journalArticle

9 Citations (Scopus)
4 Downloads (Pure)

Abstract

Multiple sclerosis (MS) is an inflammatory demyelinating disease in which cytokines produced by immune cells that infiltrate the brain and spinal cord play a central role. We show here that the IL-12p35, the alpha subunit of IL-12 or IL-35 cytokine, might be an effective biologic for suppressing neuroinflammatory responses and ameliorating the pathology of experimental autoimmune encephalomyelitis (EAE), the mouse model of human MS. We further show that IL-12p35 conferred protection from neuropathy by inhibiting the expansion of pathogenic Th17 and Th1 cells and inhibiting trafficking of inflammatory cells into the brain and spinal cord. In addition, in vitro exposure of encephalitogenic cells to IL-12p35 suppressed their capacity to induce EAE by adoptive transfer. Importantly, the IL-12p35-mediated expansion of Treg and Breg cells and its amelioration of EAE correlated with inhibition of cytokine-induced activation of STAT1/STAT3 pathways. Moreover, IL-12p35 inhibited lymphocyte proliferation by suppressing the expressions of cell-cycle regulatory proteins. Taken together, these results suggest that IL-12p35 can be exploited as a novel biologic for treating central nervous system autoimmune diseases and offers the promise of ex vivo production of large amounts of Tregs and Bregs for immunotherapy.

Original languageEnglish
Article number1258
JournalFrontiers in Immunology
Volume8
DOIs
Publication statusPublished - 5 Oct 2017

Fingerprint

Interleukin-12 Subunit p35
Encephalomyelitis
Autoimmune Experimental Encephalomyelitis
Cytokines
Multiple Sclerosis
Spinal Cord
Regulatory B-Lymphocytes
Autoimmune Diseases of the Nervous System
Cell Cycle Proteins
Adoptive Transfer
Central Nervous System Diseases
Brain
Demyelinating Diseases
Regulatory T-Lymphocytes
Interleukin-12
Immunotherapy
Lymphocytes
Pathology

Keywords

  • biological
  • multiple sclerosis
  • experimental autoimmune encephalomyelitis
  • IL-12p35
  • Breg cells
  • Treg cells
  • STATs
  • cytokine signaling

Cite this

Choi, J. K., Dambuza, I. M., He, C., Yu, C-R., Uche, A. N., Mattapallil, M. J., ... Egwuagu, C. E. (2017). IL-12p35 Inhibits Neuroinflammation and Ameliorates Autoimmune Encephalomyelitis. Frontiers in Immunology, 8, [1258]. https://doi.org/10.3389/fimmu.2017.01258

IL-12p35 Inhibits Neuroinflammation and Ameliorates Autoimmune Encephalomyelitis. / Choi, Jin Kyeong; Dambuza, Ivy M; He, Chang; Yu, Cheng-Rong; Uche, Anita N; Mattapallil, Mary J; Caspi, Rachel R; Egwuagu, Charles E.

In: Frontiers in Immunology, Vol. 8, 1258, 05.10.2017.

Research output: Contribution to journalArticle

Choi, JK, Dambuza, IM, He, C, Yu, C-R, Uche, AN, Mattapallil, MJ, Caspi, RR & Egwuagu, CE 2017, 'IL-12p35 Inhibits Neuroinflammation and Ameliorates Autoimmune Encephalomyelitis', Frontiers in Immunology, vol. 8, 1258. https://doi.org/10.3389/fimmu.2017.01258
Choi, Jin Kyeong ; Dambuza, Ivy M ; He, Chang ; Yu, Cheng-Rong ; Uche, Anita N ; Mattapallil, Mary J ; Caspi, Rachel R ; Egwuagu, Charles E. / IL-12p35 Inhibits Neuroinflammation and Ameliorates Autoimmune Encephalomyelitis. In: Frontiers in Immunology. 2017 ; Vol. 8.
@article{b3a9015da4344010aa8c56a4de763e0b,
title = "IL-12p35 Inhibits Neuroinflammation and Ameliorates Autoimmune Encephalomyelitis",
abstract = "Multiple sclerosis (MS) is an inflammatory demyelinating disease in which cytokines produced by immune cells that infiltrate the brain and spinal cord play a central role. We show here that the IL-12p35, the alpha subunit of IL-12 or IL-35 cytokine, might be an effective biologic for suppressing neuroinflammatory responses and ameliorating the pathology of experimental autoimmune encephalomyelitis (EAE), the mouse model of human MS. We further show that IL-12p35 conferred protection from neuropathy by inhibiting the expansion of pathogenic Th17 and Th1 cells and inhibiting trafficking of inflammatory cells into the brain and spinal cord. In addition, in vitro exposure of encephalitogenic cells to IL-12p35 suppressed their capacity to induce EAE by adoptive transfer. Importantly, the IL-12p35-mediated expansion of Treg and Breg cells and its amelioration of EAE correlated with inhibition of cytokine-induced activation of STAT1/STAT3 pathways. Moreover, IL-12p35 inhibited lymphocyte proliferation by suppressing the expressions of cell-cycle regulatory proteins. Taken together, these results suggest that IL-12p35 can be exploited as a novel biologic for treating central nervous system autoimmune diseases and offers the promise of ex vivo production of large amounts of Tregs and Bregs for immunotherapy.",
keywords = "biological, multiple sclerosis, experimental autoimmune encephalomyelitis, IL-12p35, Breg cells, Treg cells, STATs, cytokine signaling",
author = "Choi, {Jin Kyeong} and Dambuza, {Ivy M} and Chang He and Cheng-Rong Yu and Uche, {Anita N} and Mattapallil, {Mary J} and Caspi, {Rachel R} and Egwuagu, {Charles E}",
note = "The authors thank Rafael Villasmil (NEI FLOW Cytometry Core facility) and Dr. Venkat Mohanram (Laboratory of Immunology, NEI, NIH) for assistance with FACS analysis. NIH/NEI Intramural grant ZIA EY000262-21 (CE) and NIH/NEI Intramural grant ZIA EY000184-34 (RC) provided funding for this Research. The Supplementary Material for this article can be found online at https://www.frontiersin.org/article/10.3389/fimmu.2017.01258/full#supplementary-material.",
year = "2017",
month = "10",
day = "5",
doi = "10.3389/fimmu.2017.01258",
language = "English",
volume = "8",
journal = "Frontiers in Immunology",
issn = "1664-3224",
publisher = "Frontiers Media S.A.",

}

TY - JOUR

T1 - IL-12p35 Inhibits Neuroinflammation and Ameliorates Autoimmune Encephalomyelitis

AU - Choi, Jin Kyeong

AU - Dambuza, Ivy M

AU - He, Chang

AU - Yu, Cheng-Rong

AU - Uche, Anita N

AU - Mattapallil, Mary J

AU - Caspi, Rachel R

AU - Egwuagu, Charles E

N1 - The authors thank Rafael Villasmil (NEI FLOW Cytometry Core facility) and Dr. Venkat Mohanram (Laboratory of Immunology, NEI, NIH) for assistance with FACS analysis. NIH/NEI Intramural grant ZIA EY000262-21 (CE) and NIH/NEI Intramural grant ZIA EY000184-34 (RC) provided funding for this Research. The Supplementary Material for this article can be found online at https://www.frontiersin.org/article/10.3389/fimmu.2017.01258/full#supplementary-material.

PY - 2017/10/5

Y1 - 2017/10/5

N2 - Multiple sclerosis (MS) is an inflammatory demyelinating disease in which cytokines produced by immune cells that infiltrate the brain and spinal cord play a central role. We show here that the IL-12p35, the alpha subunit of IL-12 or IL-35 cytokine, might be an effective biologic for suppressing neuroinflammatory responses and ameliorating the pathology of experimental autoimmune encephalomyelitis (EAE), the mouse model of human MS. We further show that IL-12p35 conferred protection from neuropathy by inhibiting the expansion of pathogenic Th17 and Th1 cells and inhibiting trafficking of inflammatory cells into the brain and spinal cord. In addition, in vitro exposure of encephalitogenic cells to IL-12p35 suppressed their capacity to induce EAE by adoptive transfer. Importantly, the IL-12p35-mediated expansion of Treg and Breg cells and its amelioration of EAE correlated with inhibition of cytokine-induced activation of STAT1/STAT3 pathways. Moreover, IL-12p35 inhibited lymphocyte proliferation by suppressing the expressions of cell-cycle regulatory proteins. Taken together, these results suggest that IL-12p35 can be exploited as a novel biologic for treating central nervous system autoimmune diseases and offers the promise of ex vivo production of large amounts of Tregs and Bregs for immunotherapy.

AB - Multiple sclerosis (MS) is an inflammatory demyelinating disease in which cytokines produced by immune cells that infiltrate the brain and spinal cord play a central role. We show here that the IL-12p35, the alpha subunit of IL-12 or IL-35 cytokine, might be an effective biologic for suppressing neuroinflammatory responses and ameliorating the pathology of experimental autoimmune encephalomyelitis (EAE), the mouse model of human MS. We further show that IL-12p35 conferred protection from neuropathy by inhibiting the expansion of pathogenic Th17 and Th1 cells and inhibiting trafficking of inflammatory cells into the brain and spinal cord. In addition, in vitro exposure of encephalitogenic cells to IL-12p35 suppressed their capacity to induce EAE by adoptive transfer. Importantly, the IL-12p35-mediated expansion of Treg and Breg cells and its amelioration of EAE correlated with inhibition of cytokine-induced activation of STAT1/STAT3 pathways. Moreover, IL-12p35 inhibited lymphocyte proliferation by suppressing the expressions of cell-cycle regulatory proteins. Taken together, these results suggest that IL-12p35 can be exploited as a novel biologic for treating central nervous system autoimmune diseases and offers the promise of ex vivo production of large amounts of Tregs and Bregs for immunotherapy.

KW - biological

KW - multiple sclerosis

KW - experimental autoimmune encephalomyelitis

KW - IL-12p35

KW - Breg cells

KW - Treg cells

KW - STATs

KW - cytokine signaling

U2 - 10.3389/fimmu.2017.01258

DO - 10.3389/fimmu.2017.01258

M3 - Article

C2 - 29051763

VL - 8

JO - Frontiers in Immunology

JF - Frontiers in Immunology

SN - 1664-3224

M1 - 1258

ER -